RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ADC Therapeutics Stock

ADC Therapeutics Liabilities 2024

ADC Therapeutics Liabilities

503.03 M USD

Ticker

ADCT

ISIN

CH0499880968

WKN

A2PSR8

In 2024, ADC Therapeutics's total liabilities amounted to 503.03 M USD, a 14.22% difference from the 440.4 M USD total liabilities in the previous year.

ADC Therapeutics Aktienanalyse

What does ADC Therapeutics do?

ADC Therapeutics SA is a biopharmaceutical company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of cancer. Founded in 2011, the company is headquartered in Lausanne, Switzerland. ADCs are customized drugs that consist of an antibody and a cytotoxic drug. The antibody is designed to specifically transport the cytotoxic drug to cancer cells and release it there to destroy the cancer cells. ADC Therapeutics uses a proprietary technology platform called Pyrrolobenzodiazepine (PBD) to manufacture ADCs that have high efficacy and improved safety. The company's business model involves developing and commercializing ADCs in various stages of research, clinical development, and market launch, in collaboration with partners from the pharmaceutical industry. ADC Therapeutics focuses on different types of cancer, including solid tumors such as breast cancer, lung cancer, prostate cancer, and colorectal cancer, as well as hematological tumors such as lymphomas and leukemias. The company has several ADC products in clinical development, including Camidanlumab tesirin (Cami) for the treatment of Hodgkin lymphomas and diffuse large B-cell lymphomas, and ADCT-601 for the treatment of solid tumors overexpressing the HORM2 receptor. ADC Therapeutics has also formed partnerships with other companies, such as Genmab, AstraZeneca, Adagene, and BioNTech, to further develop and commercialize its technology and products. The company aims to improve the quality of life for cancer patients worldwide by providing innovative drugs. ADC Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing ADC Therapeutics's Liabilities

ADC Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating ADC Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing ADC Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

ADC Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in ADC Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about ADC Therapeutics stock

What is the level of liabilities of ADC Therapeutics this year?

ADC Therapeutics has a debt balance of 503.03 M USD this year.

What were the liabilities of ADC Therapeutics compared to the previous year?

The liabilities of ADC Therapeutics have increased by 14.22% increased compared to the previous year.

What are the consequences of high debt for investors of ADC Therapeutics?

High liabilities can pose a risk for investors of ADC Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in ADC Therapeutics?

Low liabilities mean that ADC Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of ADC Therapeutics affect the company?

An increase in liabilities of ADC Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of ADC Therapeutics affect the company?

A decrease in the liabilities of ADC Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of ADC Therapeutics?

Some factors that can influence the liabilities of ADC Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of ADC Therapeutics so important for investors?

The liabilities of ADC Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can ADC Therapeutics take to modify the liabilities?

To change its liabilities, ADC Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does ADC Therapeutics pay?

Over the past 12 months, ADC Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ADC Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of ADC Therapeutics?

The current dividend yield of ADC Therapeutics is .

When does ADC Therapeutics pay dividends?

ADC Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ADC Therapeutics?

ADC Therapeutics paid dividends every year for the past 0 years.

What is the dividend of ADC Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ADC Therapeutics located?

ADC Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von ADC Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ADC Therapeutics from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did ADC Therapeutics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of ADC Therapeutics in the year 2023?

In the year 2023, ADC Therapeutics distributed 0 USD as dividends.

In which currency does ADC Therapeutics pay out the dividend?

The dividends of ADC Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ADC Therapeutics

Our stock analysis for ADC Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ADC Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.